Capoten

(Captopril)

ApprovedSmall molecule

Captopril is used to treat high blood pressure and heart failure by helping blood vessels relax and improving blood flow, which reduces the workload on the heart.[2] Capoten is currently approved and in use across 17 indications[4].[1]

Capoten is one of 469 small molecule programs targeting Heart Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

468

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Heart FailureActive, not recruiting

Rheumatic DiseaseActive, not recruiting

Congestive Heart FailureActive, not recruiting

Myocardial InfarctionActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Primary AldosteronismActive, not recruiting

Kidney FailureActive, not recruiting

Diabetic RetinopathyActive, not recruiting

COVID-19Approved

Essential HypertensionApproved

Heart FailureApproved

Active, not recruiting

Rheumatic DiseaseApproved

Active, not recruiting

Congestive Heart FailureApproved

Active, not recruiting

Myocardial InfarctionApproved

Active, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Primary AldosteronismPreclinical

Active, not recruiting

Kidney FailureApproved

Active, not recruiting

Diabetic RetinopathyApproved

Active, not recruiting

COVID-19Approved

Approved

Essential HypertensionApproved

Approved

Showing 10 of 17 indications

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Capoten

SStandard Chem. & Pharm. Co., Ltd.

Approved

27 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Nitrostat

VViatris Specialty LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension2 trials

Treatment of Supine Hypertension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223717·152 enrolled

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

Terminated·VVanderbilt University·Phase 1·NCT01292694·12 enrolled

Heart Failure2 trials

Study of Drug Therapy for Pediatric Heart Failure

Unknown status·CChina National Center for Cardiovascular Diseases··NCT06039540·200 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

Type 2 Diabetes Mellitus1 trial

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Completed· Novartis logo

Novartis·Phase 4·NCT00660309·45 enrolled

High Blood Pressure1 trial

Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure

Completed·IInstituto Materno Infantil Prof. Fernando Figueira·Phase 4·NCT01761916·90 enrolled

Fibrosis1 trial

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

Withdrawn·—·Phase 1/2·NCT04629651

20 more indications

Non-Small Cell Lung Cancer1 trial

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

Terminated· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00077064·81 enrolled

Stem Cell Transplantation1 trial

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

Completed·NNorthwestern University·Phase 3·NCT00004230·35 enrolled

Vasoconstriction1 trial

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Recruiting·UUniversity of Calgary··NCT05442463·200 enrolled

Unknown status·—·Phase 4·NCT04485845·39 enrolled

Tics1 trial

A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril

Completed·SSeoul National University Hospital·Phase 1·NCT06292091·12 enrolled

Severe Acute Respiratory Syndrome1 trial

Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04355429·230 enrolled

Radiation Injury1 trial

The Role and Intervention of TGF-β in Abdominal Radiation Injury

Unknown status·WWuhan University·Phase 2·NCT03613506·226 enrolled

Capillary Hemangioma1 trial

Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma

Unknown status·—·Phase 4·NCT04288700·100 enrolled

Angiotensin Converting Enzyme1 trial

Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition

Completed·IInstituto de Cardiologia do Rio Grande do Sul·Phase 4·NCT01545479·5 enrolled

Duchenne1 trial

Effect of Captopril on GLS in Duchenne Myodystrophy

Recruiting·—·Phase 1·NCT06485661·20 enrolled

Type 2 Diabetes1 trial

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

Unknown status·HHospital de Clinicas de Porto Alegre··NCT00935805·124 enrolled

Diabetic Nephropathy1 trial

Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy

Completed·SShiraz University of Medical Sciences·Phase 2/3·NCT00663949·70 enrolled

Prolonged1 trial

Rapid Versus Prolonged Inpatient Up-Titration of Captopril

Unknown status·TThe Hospital for Sick Children·Phase 2·NCT00742040·50 enrolled

Function1 trial

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

Unknown status·—·Phase 1/2·NCT01626469·24 enrolled

Glioblastoma1 trial

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed·UUniversity of Ulm·Phase 1/2·NCT02770378·10 enrolled

Type 1 Diabetic1 trial

Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs

Completed·TTanta University·N/A·NCT03660293·150 enrolled

Metastatic Cancer1 trial

In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer

Completed·NNorthwestern University·Phase 1/2·NCT00086723

Fasting Conditions1 trial

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Withdrawn· GSK logo

GSK·Phase 1·NCT04878315

Regulatory

FDA Approval Timeline[5]

Jan 17, 1985

CAPOTEN

NDA NDA018343

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Captopril. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Capoten drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Captopril compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Captopril. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA018343). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Standard Chem. & Pharm. Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Angiotensin-Converting Enzyme Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: SStandard Chem. & Pharm. Co., Ltd.

Capoten

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Hypertension2 trials

Heart Failure2 trials

Type 2 Diabetes Mellitus1 trial

High Blood Pressure1 trial

Fibrosis1 trial

Non-Small Cell Lung Cancer1 trial

Stem Cell Transplantation1 trial

Vasoconstriction1 trial

Ventricular Function1 trial

Mitral regurgitation1 trial

Metabolic Syndrome1 trial

Tics1 trial

Severe Acute Respiratory Syndrome1 trial

Radiation Injury1 trial

Capillary Hemangioma1 trial

Angiotensin Converting Enzyme1 trial

Duchenne1 trial

Type 2 Diabetes1 trial

Diabetic Nephropathy1 trial

Prolonged1 trial

Function1 trial

Glioblastoma1 trial

Type 1 Diabetic1 trial

Metastatic Cancer1 trial

Fasting Conditions1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News